Arbutus Biopharma (ABUS)
(Real Time Quote from BATS)
$3.40 USD
-0.02 (-0.59%)
Updated Jun 4, 2024 12:55 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Arbutus Biopharma Corporation [ABUS]
Reports for Purchase
Showing records 101 - 120 ( 191 total )
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Maintaining HOLD Rating During Shifts In Pipeline Priorities, But Chronic Hepatitis B Remains Core Therapeutic Focus
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; HBV Pipeline Progressing, but Remains Early
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials; Focus Shifts to ?506 and ?729 Potential Combo
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Arbutus Biopharma Corporation
Industry: Medical - Biomedical and Genetics
Upgrading to NEUTRAL Based on Valuation Post Sell-Off
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R